Collaboration with Sarah Cannon Research Institute for cancer research

Bristol Myers Squibb A meaningful step forward in expanding access to cancer research. Bristol Myers Squibb is strengthening its strategic collaboration with the Sarah Cannon Research Institute, aligning BMS’s pioneering hematology and oncology pipeline with SCRI’s Accelero model and nationwide community-based network. This partnership is transforming how clinical trials are delivered — bringing innovative therapies closer to patients and advancing health equity by reaching medically underserved communities. A strong example of how thoughtful collaboration can reshape the future of cancer care. #OneBMS #Oncology #ClinicalTrials #HealthEquity #CancerResearch #Hematology

🎗️ On Breast Cancer Awareness Month, attention centres on early detection, research, and equitable access to care. Beyond the pink ribbon lies a global effort to advance diagnostics, treatment, and patient support.🩷 In clinical research, precision data and inclusive trials play a vital role in developing targeted therapies and improving outcomes. Every dataset, every biomarker, every protocol contributes to a broader understanding of this complex disease. 🔬 💡Progress in breast cancer care depends on collaboration across sectors—uniting science, technology, and compassion to drive meaningful change. #BreastCancerAwareness #ClinicalResearch #HealthEquity #Diagnostics #Medtech #OncologyInnovation

Connecting patients to pioneering care is what drives Claudia Bujold, Vice President and Global Therapeutic Area Head for Breast Cancer and Women’s Health at Novartis. Hear her discuss what makes ESMO 2025 special, the future opportunities for patients in oncology and breast cancer care, and her common purpose in the patient care space. #ESMO2025

Game-changing cancer care is happening right here in our communities. We’re proud to be part of McKesson’s Precision Care Companion (PCC) Consortium—working alongside Ontada, Sarah Cannon Research Institute (SCRI), leading molecular testing partners, and practices in The US Oncology Network—to bring genomic testing and targeted therapies into everyday community workflows. Across 12 practices in The Network and four tumor types (lung, colon, rectal, and prostate), PCC integrates education, Molecular Tumor Boards, iKnowMed® EHR enhancements, and real‑world evidence so clinicians can efficiently order comprehensive testing and act on results faster. The impact: streamlined clinical care teams, more precise therapy selection, and new clinical trial options for patients—closer to home. Read the article to see how this collaboration is elevating community oncology: https://lnkd.in/gqHeH72Z Jason Hammonds, Heidi Floden #CommunityOncology #PrecisionMedicine #GenomicTesting #TargetedTherapies

Precision medicine holds incredible promise. And yet, it has been historically limited to specific cancer types within major academic centers or small regional networks. Through McKesson’s Precision Care Companion (PCC), we’re working to change that. A collaborative proof-of-concept designed to accelerate integration of precision medicine into clinical systems and workflows. Thanks to deep partnership across McKesson, and incredible collaboration with diagnostic testing partners, we’re learning together and shaping the systems that will expedite delivery of precision medicine within community oncology. Guardant Health, Foundation Medicine, Caris Life Sciences, Natera #PrecisionMedicine #Oncology #PrecisionCareCompanion #Collaboration #ClinicalInnovation #CancerCare #PartnershipInAction

Cancer care is evolving - and so is how we support practices. McKesson and its Precision Care Companion (PCC) Consortium are working together to enhance how community oncology practices guide patients through their treatment journey. This collaborative effort is helping patients access the right care, at the right time, closer to home. Guardant Health, Foundation Medicine, Caris Life Sciences, Natera

McKesson has launched Precision Care Companion (PCC), a consortium that brings together oncology practices, diagnostic labs and biopharma partners to accelerate the adoption of precision medicine in community settings. By integrating Ontada’s iKnowMed® electronic health record (EHR) and pairing analytics on biomarker testing rates for different cancer diagnoses, providers can efficiently order comprehensive genomic testing and receive actionable results directly into their workflow. As a result, they can prescribe the most effective targeted therapies with greater confidence and speed. #PrecisionMedicine #EHR #CommunityOncology

HRW OR:BIT, our Oncology Research: Business Insights Team, cut through the noise at this year’s ESMO - European Society for Medical Oncology Congress to uncover the key questions shaping cancer care, and what they mean for your strategy. Top insights include: -Biomarker-driven early treatment -Beyond-the-pill patient support -Equity in trial design and representation -Earlier endpoints for faster access -Adaptive trials and precision-led brand strategies Scroll through the carousel to see what’s driving smarter trials, precision care, and a shift toward truly patient-centered approaches, or alternatively click here to read the full piece: https://bit.ly/4nVAxpB Contact Marianne Ibrahim, Director and Sidak Seth, Research Manager at HRW-ORBIT@hrwhealthcare.com if you’d like to find out how these insights could shape your brand strategy. #ESMOCongress #ESMO2025 #ESMOkeytakeaways #oncologyinsights #oncology #healthcaremarketresearch

It was a privilege to have been part of the Tumor Board Establishment Facilitation Forum - DUHS in organizing Dow International Medical College’s first Mock Tumor Board, held on 25th September 2025. The initiative provided an excellent platform for medical students to engage in multidisciplinary oncology case discussions and observe collaborative clinical decision-making. Interactions with distinguished oncologists offered valuable insights into cancer care pathways and research advancements in Pakistan. This experience reinforced the importance of structured tumor boards in improving patient outcomes and highlighted the role of future physicians in promoting multidisciplinary cancer care nationwide. #MedicalEducation #Oncology #TumorBoards #DIMC #TEFF #CancerCare #HealthcareQuality #Collaboration #FuturePhysicians

🔬Proud to have co-authored the poster “Global quantitative assessment of MDT care in early-stage NSCLC”, presented at #ESMO2025. 📊This publication — presenting results from a global quantitative survey — is the penultimate in our series evaluating the role of multidisciplinary teams in patient care across 11 markets. 💡Our findings add to the growing evidence that collaborative approaches in early-stage lung cancer can improve patient outcomes. However, in today’s increasingly complex treatment landscape, key barriers to MDT success still need urgent attention — including complete biomarker information and better referral pathways between centers.. 🙏Grateful to my co-authors and the full team for their expertise, dedication and shared commitment to advancing patient care. #ESMO #Oncology #NSCLC #CancerResearch Lumanity